Search terms
Results 11 - 20 of 43 - ordered by :
Pages: 1 2 3 4 5

In clinical trials - where the sickest patients are often excluded - mortality rate is as low as 5%. Other drugs groups include beta-blockers, ACE inhibitors, and statins develeoped to lower ...

Date : 01/09/2009

[...]both over-consumption of calories and reduced physical activity are involved in childhood obesity. [...]in early childhood, overweight and obesity are associated with the classical risk factors ...

Date : 31/08/2009

Type of healthcare reimbursement system influences the achievement of cholesterol targets, reveals research presented at ESC Congress 2013 today by Dr Anselm Kai Gitt from Germany. Dr Gitt said: ...

Date : 31/08/2013

After providing blood samples and measurements of their blood pressure, height, weight and waist circumference, participants each wore an activity monitor on their thigh for 24 hours a day over a ...

Date : 31/07/2015

Renowned expert, Professor Eugene Braunwald (Brigham and Women’s Hospital and Harvard Medical School, Boston, USA) speaks to ESC Congress News about the options. “LDL-C is the principal ...

Date : 27/08/2017

Very high levels of high-density lipoprotein (HDL or “good”) cholesterol may be associated with an increased risk of heart attack and death, according to research presented today at ESC ...

Date : 25/08/2018

The intermediate-risk population was made up of participants without cardiovascular disease, including men ≥55 and women ≥60 years old with risk factors such as smoking, early renal dysfunction ...

Date : 30/08/2017

Doctors must emphasise importance of complying with treatment say researchers Thousands of statin users worldwide are suffering preventable heart attacks, simply because they are not complying with ...

Date : 07/12/2006

Experts from the European Society of Cardiology (ESC) will present a special programme.1 “Lifestyle changes appear to be responsible for falls in blood cholesterol in the general populations of ...

Date : 03/11/2017

Inclisiran—an investigational drug that “switches off” PCSK9 synthesis in the liver—lowers rates of low-density lipoprotein (LDL) cholesterol for up to one year in patients ...

Date : 29/08/2017